Navigation Links
BUSM study identifies receptor's role in regulating obesity, type 2 diabetes
Date:7/26/2012

(Boston) A recent study led by Boston University School of Medicine (BUSM) demonstrates that the A2b-type adenosine receptor, A2bAR, plays a significant role in the regulation of high fat, high cholesterol diet-induced symptoms of type 2 diabetes. The findings, which are published online in PLoS ONE, also identify A2bAR as a potential target for the treatment of type 2 diabetes.

Katya Ravid, DSc/PhD, professor of medicine and biochemistry and director of the Evans Center for Interdisciplinary Biomedical Research at BUSM, led this study. Colleagues from Ravid's lab who collaborated on this research include Hillary Johnston-Cox, BSc (MD/PhD, 2014) and Milka Koupenova-Zamor, PhD. Noyan Gokce, MD, associate professor of medicine at BUSM, and Melissa Farb, PhD, a postdoctoral fellow at BUSM, also collaborated on the study.

Diets that are high in fat and cholesterol induce changes in how the body regulates blood glucose levels. Exercise induces an increased production adenosine, a metabolite produced naturally by cells. A2bAR, a naturally occurring protein receptor found in the cell membrane, is activated by adenosine. This receptor is known to play an important role in regulating inflammation, which is associated with type 2 diabetes and obesity.

To examine the association of A2bAR activation with a diet high in fat and cholesterol, the researchers used an experimental model that lacked A2bAR and compared the results with a control group. When the experimental model group was given a diet high in fat and cholesterol, there was an increase in the development of obesity and signs of type 2 diabetes. The signs demonstrated in the study included elevated blood glucose levels and increased in insulin levels. When the control group was given the same diet, however, the levels of A2bAR increased, resulting in decreased insulin and glucose levels and obesity.

A novel link also was identified between the expression of A2bAR, ins
'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study associates excess maternal iodine supplementation with congenital hypothyroidism in newborns
2. New study associates excess maternal iodine supplementation with congenital hypothyroidism
3. Its a bird, not a plane: York U study finds migrating songbirds depart on time
4. Alpine Fault study shows new evidence for regular magnitude 8 earthquakes
5. Researchers study knee stress at tissue, cellular levels
6. DataONE answers the call for new tools to study the Earth in this era of Big Data science
7. Study shows economic feasibility for capturing carbon dioxide directly from the air
8. New study: Raisins as effective as sports chews for fueling workouts
9. PSU study finds caffeinated coastal waters
10. New study announced that will use genetics to test for Alzheimers risk
11. Study points to causes of high dolphin deaths in Gulf of Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... University of Nottingham have won a prestigious international ... Professor Liz Sockett and colleagues at Nottingham, ... University of Hiroshima, Japan, have jointly been awarded ... honour of their bacterial research. Daiwa Adrian ...
... Police Launch Multi-agency Data Interoperability System, ... (OTC Bulletin Board: BKYI), a leader in ... and its partner,DaProSystems today announced a contract ... a mobile data solution. Harrisonburg,s police,department has ...
... technology developed by a University of Colorado at Boulder ... vents has been used to identify unexpected bacteria strains ... cystic fibrosis, findings that may lead to more effective ... nucleic acid gene sequencing to rapidly detect, identify and ...
Cached Biology News:Honor for UK-Japanese research 2Wireless Public Safety Solution From BIO-key(R) and DaProSystems Links Virginia Law Enforcement Agencies 2Wireless Public Safety Solution From BIO-key(R) and DaProSystems Links Virginia Law Enforcement Agencies 3CU-Boulder technology used to identify unexpected bacteria in cystic fibrosis patients 2
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... HOUSTON and PHILADELPHIA , ... the most demanding and unforgiving environments. Human exploration of ... cognitive performance to ensure mission safety and success, and ... cognitive performance for mission success, little is known about ... aspects of cognition are primarily affected. Now, ...
(Date:11/26/2014)... November 26, 2014 PMG Research, Inc. ... PMG Research is a network of sites that provide clinical ... over 2 million patient lives through its partnerships with large ... of 11 hub site locations in the Southeastern United States ... term of the board will be held by: ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
Breaking Biology Technology:Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... (LSE: SHP, NASDAQ: SHPGY) the global specialty,biopharmaceutical company announces results ... Q2 2008 Financial Highlights, - Product sales up ... up 64% to $409m - New product sales(1) $243m, ... up 35% to $776m - US GAAP earnings per ...
... Neuropharmaceuticals,Inc., a formulator of pharmaceuticals for direct-to-the-brain ... capital Series A,financing. Co-leads in the funding ... Partners. Other investors include High Country,Venture and ... proprietary drug development process that makes use ...
... 32% Over Second Quarter 2007, - EPS of $0.63 per Basic Share, ... Charges of $1.36 per Basic Share, Increase of ... 56% Over Second Quarter 2007, SILVER ... announced its results of,operations for the quarter ended June 30, 2008., ...
Cached Biology Technology:Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 2Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 3Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 4Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 5Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 6Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 7Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 8Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 9Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 10Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 11Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 12Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 13Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 14Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 15Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 16Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 17Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 18Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 19Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 20Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 21Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 22Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 23Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 24Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 25Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 26Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 27Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 28Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 29Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 30Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 31Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 32Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 33Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 3United Therapeutics Reports Second Quarter 2008 Financial Results 2
... Phosphate Assay Kit is based on quantification ... Green, molybdate and free orthophosphate. The rapid ... conveniently measured on a spectrophotometer (600-660 nm) ... colorimetric assay kits have been optimized to ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
...
Biology Products: